We have investigated hepatitis C virus (HCV) viremia before and after orthotopic liver transplantation (OLT). 38 patients were examined; 16 were anti-HCV positive and 22 anti-HCV negative pre-OLT in a RIBA-2 test (Ortho Diagnostic Systems Inc., Westwood, MA). HCV-RNA was detected using a modified nested polymerase chain reaction in 14/38 and 10/38 patients before and after OLT, respectively. 7 of these 14 subjects who were HCV-RNA positive before OLT were also positive for serum hepatitis B surface antigen. After 
Introduction
Hepatitis C virus (HCV)' is a major etiological agent ofnon-Anon-B infection (NANB) (1) . Hepatitis C virus-related chronic liver diseases are increasingly an indication for orthotopic liver transplantation (OLT). Indeed, HCV tests are positive in 40% ofcandidates for OLT in our center (D. Samuel, personal communication).
It has recently been suggested by studies based on serological tests that the liver graft might be infected by HCV (2) . However, serological assays are difficult to interpret in the context ofimmunosuppression. In addition, tests for HCV antigens are not available and assays only detect antibodies to structural and nonstructural proteins (1) . The distinction between recur-1. Abbreviations used in this paper: HBSAg, Hepatitis B surface antigen; HBV, Hepatitis B Virus; NANB, Non-A, Non-B; NPCR, nested polymerase chain reaction; OLT, orthotopic liver transplantation; PCR, polymerase chain reaction. rences and acquired HCV infections due, in particular, to blood transfusions during OLT is therefore a major problem.
We have used the polymerase chain reaction (PCR) procedure (3) to detect HCV RNA (4) in the serum ofpatients before and after OLT and to compare the corresponding nucleotide sequences in a hypervariable domain of the genome.
Methods
Patients. 38 patients who underwent liver transplantation between October 1986 and March 1989 at the Villejuifliver transplant center were studied retrospectively. The patients were divided into three groups according to their HCV and HBV serologies at the time of OLT.
Group 1 comprised 16 subjects with a positive test result for anti-HCV antibodies; 7 were also HBsAg-positive. The indications for OLT in this group were HBsAg-positive fulminant hepatitis (n = 2), HBsAgpositive cirrhosis (n = 5), NANB cirrhosis (n = 8), and primary liver cancer (n = 1).
Group 2 comprised 12 patients who were anti-HCV-negative and HBsAg-positive. The indications for liver transplantation were cirrhosis (n = 8), primary liver cancer (n = 2), and fulminant hepatitis (n = 2).
Group 3 (controls) comprised 10 anti-HCV and HBsAg-negative patients with primary biliary cirrhosis (n = 7) or primary sclerosing cholangitis (n = 3).
Posttransplant immunosuppressive therapy consisted ofa combination of prednisone, cyclosporin, and azathioprine. Each patient received blood products from an average of 103 (SD = 45) different donors. All the HBsAg-positive patients (n = 19) were treated with high doses (10,000 IU) of anti-HBs immunoglobulins (HBsIg) during OLT and throughout follow-up to maintain anti-HBs levels above 100 IU/ liter (5) . Neither the transfusion products nor the liver donors were screened for anti-HCV antibodies at the time of the study.
Procedures
Serum samples used for serology and PCR were obtained an average of 2 mo before OLT (SD = 1.7) and 12 mo after OLT (SD = 6.5).
Serological tests
Anti-HCVantibodies. The presence ofanti-HCV antibodies was tested for using a recombinant immunoblot assay RIBA-2 (Ortho Diagnostic Systems Inc., Westwood, MA.). This test detects antibodies to epitopes located in capsid (c22) and nonstructural genes (c33, c100.3, and 51 1).
HBV markers. Serum HBsAg, anti-HBs, anti-HBc, and HBeAg titers were measured by means of radioimmunoassay using standard kits (Abbott Diagnostics, South Pasadena, CA). HBV DNA in serum was detected by a spot test assay as previously described (6 NPCR is a highly sensitive two-step procedure in which the products of a first PCR using "outer" primers are reamplified using a second set of "inner" primers located within the previously amplified sequence (4). A major drawback ofthe conventional nesting strategy is linked to the opening of the reaction tube after the first amplification step, giving a risk ofcontaminating the second reaction with amplicons (7). To overcome this problem, we have developed a new protocol for NPCR without reopening the reaction tube between the two steps ofthe procedure. Two different sets of primers were used for each cDNA (Table I ). The first set (primers SRI, SR2, SF1, and SF2) is located within the 5' terminal sequence (5NC) ofthe HCV genome (8) which is conserved in all HCV isolates. The second set ofprimers (82.0,82.1,82.2, and 82.3), situated within a hypervariable region of the HCV genome coding for an envelope protein "E2/NSI" (9) , was chosen to test the variability of HCV sequences.
ANALYSIS OF PCR PRODUCTS
20 Ml ofeach nested PCR product was analyzed by means ofelectrophoresis on a 1.5% agarose gel. Bands were visualized by ethidium bromide staining, transferred to nylon membranes (Gene-Screen Plus; New England Nuclear, Boston, MA) (10) , and hybridized with 32P-labeled probes (Table I) .
SPECIFICITY AND SENSITIVITY CONTROLS
To detect carry-over, we performed HCV-PCR with the following controls: (a) serum-free lysis buffer for the detection of contamination at every step of the procedure, (b) three negative sera (blood donors) for 12 test sera, (c) the PCR mix alone. Measures for the prevention of carry over included drastic separation ofpre-PCR and post-PCR steps.
It has been shown that most false results with PCR arise during handling ofamplification products (11) . A standard positive control from an HCV-infected patient with postransfusional hepatitis yielded positive results at dilutions up to 10-8. Sequencing ofthe E2/NSI region PCR products obtained with primers 82.0, 82.1, 82.2 and 82.3 were purified using the low-melting-point agarose procedure (12) and sequenced using T7 DNA polymerase (Pharmacia, Uppsala, Sweden) and primer 82.1.
Histology
Liver graft biopsies were obtained after OLT at the time of serum collection.
Statistical analysis
Data were analyzed using Fisher's exact test.
Results
Before OLT. HCV RNA was detected in 9 of the 16 patients who were anti-HCV-positive (group 1), 5 of the 12 who were anti-HCV-negative (group 2) and none of the controls (group 3). After OLT. HCV RNA was detected in a total of 10 patients: 3, 4, and 3 in groups 1, 2, and 3, respectively (Table II and Fig. 1 ). Four patients scored positive for HCV RNA both before and after OLT and six were positive only after OLT (Table II) .
The four patients with a positive amplification ofthe highly conserved sequence (primers 5NC) both before and after OLT were then tested with primers encompassing the hypervariable domain, located in the 5' part of E2/NS1 sequence (13) . Vari- 
* Chronic active hepatitis. § Primary liver cancer. "lPrimary biliary cirrhosis ' Primary sclerosing cholangitis. able sequences could be amplified both pre-and post-OLT in two patients (8, 13) . Fig. 2 and Table III show the results oW tained in these two cases and in a patient (No. 29) with acquired, probably posttransfusional hepatitis. In both cases preand post-OLT nucleotide sequences were highly conserved (95 and 96%). In addition, the degree of homology was higher between paired pre-and post-OLT isolates than when the five isolates were compared each other or with published American (14) and Japanese isolates (15) (Fig. 2) . These results demonstrated that the liver graft was indeed infected by the pre-OLT strain in both cases. Table II compares the results of the anti-HCV and HCV RNA assays. Two of the 20 patients who were anti-HCV negative after OLT, scored positive for HCV RNA. Conversely, 10 of the 18 subjects who were anti-HCV positive after OLT were HCV RNA-negative.
Liver histology was available for all patients. Chronic Hepatitis was significantly more frequent in patients with positive HCV viremia (6/10 vs 2/28; P < 0.01). It is noteworthy that none of the 6 patients with HCV viremia and chronic hepatitis had evidence of associated HBV infection. Among the 28 HCV-RNA negative patients, 2 showed HBV-related chronic hepatitis. These 2 subjects were the only subjects among the 19 HBsAg positive individuals who showed evidence for HBV recurrence as assessed by positive serum HBs Ag and HBV DNA assays. This low rate of recurrence is explained by a low prevalence of HBV replication before OLT (1/19) together with long-term immunoprophylaxis with HBsIg (16). Sequences of HCV RNA from 3 patients in the present study are shown, including 2 with HCV recurrence (patients 8 and 13 in Table  II ) and 1 with posttransfusional hepatitis (patient 29 in Table II) . Lanes I and 2 correspond to pre-OLT and post-OLT HCV RNA sequences in patient 8, while lanes 1' and 2' correspond to those of patient 13 It is also interesting to note that some ofthese patients bore markers of both HCV and HBV infection before OLT. It is tempting to speculate that such coinfection might attenuate HCV viremia before OLT and, thus, the risk of HCV reinfection. In addition anti-HBs antibody preparations, used to prevent HBV recurrences in these subjects, might contain anti-HCV antibodies although the batches we have tested have been negative in a RIBA-II assay. 6 of the 38 subjects had acquired HCV infection after OLT. It is noteworthy that this study was undertaken before the exclusion of anti-HCV positive blood and liver donors became possible. Although screening ofblood products with serological tests is quite efficient (20), the number of donors necessary to transfuse organ recipients is large, and the frequency of transfusion-related infection might well remain high. 1364 Feray, Samuel, (21) . Taken together our results indicate that HCV may be a significant cause of liver disease following OLT.
Finally, although anti-HCV antibodies were sought using the RIBA-2 test, 2/20 ofthe patients who were anti-HCV negative after OLT were HCV RNA-positive. Thus serological status after OLT was not able to distinguish recurrent from acquired, posttransfusional HCV infection. Therefore, detection by PCR ofHCV RNA is currently the only method for appraising HCV infection following liver transplantation.
